Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes

Abstract

Letter to Blood| April 6, 2023 Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes Clinical Trials & Observations Tariq Kewan, Tariq Kewan Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OHDepartment of Hematology and Oncology, Yale University, New Haven, CT https://orcid.org/0000-0003-4651-5125 Search for other works by this author on: This Site PubMed Google Scholar Waled Bahaj, Waled Bahaj Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Search for other works by this author on: This Site PubMed Google Scholar Arda Durmaz, Arda Durmaz Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OHSystems Biology and Bioinformatics Department, School of Medicine, Case Western Reserve University, Cleveland, OH https://orcid.org/0000-0001-8394-600X Search for other works by this author on: This Site PubMed Google Scholar Mai Aly, Mai Aly Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OHFaculty of Medicine, Assiut University, Assiut, Egypt https://orcid.org/0000-0002-3926-6856 Search for other works by this author on: This Site PubMed Google Scholar Olisaemeka D. Ogbue, Olisaemeka D. Ogbue Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Search for other works by this author on: This Site PubMed Google Scholar Hetty E. Carraway, Hetty E. Carraway Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH https://orcid.org/0000-0001-5241-3614 Search for other works by this author on: This Site PubMed Google Scholar Mikkael A. Sekeres, Mikkael A. Sekeres Department of Hematology and Oncology, University of Miami, Miami, FL Search for other works by this author on: This Site PubMed Google Scholar Valeria Visconte, Valeria Visconte Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Search for other works by this author on: This Site PubMed Google Scholar Carmelo Gurnari, Carmelo Gurnari Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OHDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy https://orcid.org/0000-0001-6829-5544 Search for other works by this author on: This Site PubMed Google Scholar Jaroslaw P. Maciejewski Jaroslaw P. Maciejewski Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Search for other works by this author on: This Site PubMed Google Scholar Blood (2023) 141 (14): 1768–1772. https://doi.org/10.1182/blood.2022018896 Article history Submitted: October 28, 2022 Accepted: January 17, 2023 Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Request Permissions Cite Icon Cite Search Site Citation Tariq Kewan, Waled Bahaj, Arda Durmaz, Mai Aly, Olisaemeka D. Ogbue, Hetty E. Carraway, Mikkael A. Sekeres, Valeria Visconte, Carmelo Gurnari, Jaroslaw P. Maciejewski; Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes. Blood 2023; 141 (14): 1768–1772. doi: https://doi.org/10.1182/blood.2022018896 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBlood Search Subjects: Clinical Trials and Observations, Myeloid Neoplasia TO THE EDITOR: Myelodysplastic syndrome (MDS) represents a heterogeneous group of disorders encompassing a wide range of pathologically distinct subtypes associated with different outcomes. Until recently, clinical and cytogenetic features have dominated the pathological classification and the prognostication of MDS.1-3 The wide use of next-generation sequencing and subsequent molecular studies have examined the impact of different genetic alterations on the pathogenetic derivation, diagnostic assignment, and disease prognosis.4-9 The latest contribution to the task of adopting molecular features into the clinical prognostic scheme is represented by the Molecular International Prognostic Scoring System (IPSS-M), a product of the International Working Group for Prognosis in MDS (IWG-PM).10 Here, we took advantage of a large cohort of patients with MDS (n = 1281, supplemental Methods, available on the Blood website) to validate the novel IPSS-M and to compare the score with the...